Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.94 |
| ▸ | CA1 | P00915 | 4/20 | 0.94 |
| ▸ | CA2 | P00918 | 4/20 | 0.94 |
| ▸ | CA7 | P43166 | 4/20 | 0.94 |
| ▸ | CA9 | Q16790 | 4/20 | 0.94 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.94 |
| ▸ | MAPT | P10636 | 3/20 | 0.94 |
| ▸ | CA4 | P22748 | 3/20 | 0.94 |
| ▸ | CA6 | P23280 | 3/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.94 |
| ▸ | CA3 | P07451 | 2/20 | 0.94 |
| ▸ | CA5A | P35218 | 2/20 | 0.94 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.94 |
| ▸ | SELL | P14151 | 1/20 | 0.94 |
| ▸ | HPGD | P15428 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gallic Acid SCHEMBL1845406 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL678990 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL15012 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL4918056 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL8088102 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL29484566 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL30375631 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL9678849 | 0.94 | CA12 (0.94) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL135340 | 0.94 | CA12 (0.94) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL1334688 | 0.94 | CA12 (0.94) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4070801-A1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | Nutrition 21, LLC (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3513790-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | JDS Therapeutics, LLC (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-2448412-B1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | JDS THERAPEUTICS LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9700546-B2 | Trivalent chromium compounds, compositions and methods of use | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160354353-A9 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | LONZA CONSUMER HEALTH INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160220581-A1 | CHROMIUM COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DIABETIC RETINOPATHY | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2016-08-04 | — | — | US | disclosed |
| CN-105749253-A | Methods And Compositions For The Treatment And Prevention Of Hypoglycemia And Related Disorders | JDS治疗有限公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-103702672-B | Insulin and chromium compositions for the prevention and treatment of diabetes, hypoglycemia and related conditions | JDS THERAPEUTICS, LLC (US) | 2016-04-27 | — | — | CN | disclosed |
| US-20150306083-A1 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS INC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150224140-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2015-08-13 | — | — | US | disclosed |
| US-8933022-B2 | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders | JDS THERAPEUTICS, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2012119007-A1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | N21 ACQUISITION HOLDING, LLC (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20120225134-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HYPOGLYCEMIA AND RELATED DISORDERS | N21 ACQUISITION HOLDING, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| EP-2448412-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | Nutrition 21, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120100228-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2012-04-26 | — | — | US | disclosed |
| WO-2011002939-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | NUTRITION 21, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20090092560-A1 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2012770-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Interhealth Nutraceuticals, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121312-A9 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS INC (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007121312-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100228-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | SLC2A3, SLC2A1, SLC2A2 | CA12 597/4885CA1 368/4885CA2 205/4885 |
| US-20160220581-A1 | CHROMIUM COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DIABETIC RETINOPATHY | RBP4, RBP1, ALDH1A2 | CA12 128/4885CA1 489/4885CA2 156/4885 |
| US-20150224140-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | SLC2A3, SLC2A1, SLC2A2 | CA12 597/4885CA1 368/4885CA2 205/4885 |
| US-20120225134-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HYPOGLYCEMIA AND RELATED DISORDERS | IAPP, GCG, PYGL | CA12 44/4885CA1 64/4885CA2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.